B-Raf IN 13 NEW
Price | $1520 |
Package | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: B-Raf IN 13 | CAS No.: 2573782-74-6 |
Purity: 98.39% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | B-Raf IN 13 |
Description | B-Raf IN 13 is a potent B-Raf inhibitor with anticancer activity, demonstrating an IC50 of 3.55 nM in the [BRAF V600E] enzyme assay. |
Storage | Shipping with blue ice. |
Keywords | 1Propanesulfonamide,N[2chloro3[(3,4dihydro3,5dimethyl4oxo6quinazolinyl)oxy]5fluorophenyl] | B-Raf IN 13 |
Inhibitors Related | Regorafenib monohydrate | Doramapimod | Vemurafenib | Sulindac sulfide | Sorafenib | Regorafenib | Dabrafenib | Sorafenib tosylate | PLX-4720 | LY3009120 | Pelitinib | GW 441756 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$30.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$2120.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.00/1kg |
VIP1Y
|
Hangzhou Lin'an tianhong biotechnology co.,ltd.
|
2024-07-26 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY